NeoGenomics, Inc.
Here’s whether NeoGenomics, Inc. (NEO) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-8.69% over 10 days); weak 1-year return of -12.7%; 3-month momentum negative (-34.7%); rising volume on a downtrend (distribution, 1.30x avg). Currently 39.2% off its 52-week high. Score: -6/7.
NEO is trading below its 200-day MA ($9.35) — a key warning sign the longer-term trend is under pressure. An RSI of 67.8 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -12.7% compares to +35.1% for SPY (trailed the market by 47.8%). The current 39.2% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.